Beta Bionics, Inc.
Case Overview
39 Days Left to Seek Lead Plaintiff
| Lead Plaintiff Deadline: | Lead Plaintiff Deadline:11/03/2026 |
| Status: | Status:Investigating |
| Company Name: | Company Name:Beta Bionics, Inc. |
| Court: | Court:Central District of California |
| Case Number: | Case Number:2:26cv09999 |
| Class Period: | Class Period:07/30/2025 - 02/24/2026 |
| Ticker: | Ticker:BBNX |
| Related Attorneys: | Lead Attorneys:Thomas W. Elrod |
| Related Practices: | Related Practices:Securities |
The lawsuit alleges that Beta Bionics made false and/or misleading statements and failed to disclose to investors that: (i) the Company’s iLet Bionic Pancreas insulin pump (“iLet”) was malfunctioning and dosing patients with dangerously high levels of insulin, causing hypoglycemic events; (ii) the FDA had raised these issues in a Form 483 it sent to Beta Bionics; (iii) there were thousands of customer complaints back-filed with the FDA in response to the Form 483, including hundreds of life-threatening events requiring significant medical intervention; and (iv) the FDA was not satisfied with the Company’s response to the issue, as Beta Bionics had failed to implement meaningful corrective actions.
On January 8, 2026, Beta Bionics reported its fourth quarter 2025 earnings results, revealing an unexpected miss on new iLet patient starts. On this news, Beta Bionics’ stock price dropped $11.85, or 37%, to close at $20.14 per share on January 9, 2026.
On January 30, 2026, Beta Bionics filed a Form 8-K with the U.S. Securities & Exchange Commission, revealing that the FDA had sent the Company a warning letter connected to its earlier Form 483. The Company revealed that the FDA’s concerns were more serious than they had previously acknowledged, and that the FDA took issue with Beta Bionics’ quality management system for iLet and the Company’s failure to take corrective action based on the Form 483. On this news, Beta Bionics’ stock price fell $0.96, or 6.5%, to close at $13.83 per share on January 30, 2026.
Then, on February 24, 2026, the FDA publicly released its warning letter, revealing the FDA’s concerns with iLet’s underlying issues and stating that any iLet malfunction or hypoglycemia requiring medical intervention must be reported to the FDA. On this news, Beta Bionics’ stock price fell $0.50, or 3.7%, to close at $12.89 per share on February 25, 2026.
On January 8, 2026, Beta Bionics reported its fourth quarter 2025 earnings results, revealing an unexpected miss on new iLet patient starts. On this news, Beta Bionics’ stock price dropped $11.85, or 37%, to close at $20.14 per share on January 9, 2026.
On January 30, 2026, Beta Bionics filed a Form 8-K with the U.S. Securities & Exchange Commission, revealing that the FDA had sent the Company a warning letter connected to its earlier Form 483. The Company revealed that the FDA’s concerns were more serious than they had previously acknowledged, and that the FDA took issue with Beta Bionics’ quality management system for iLet and the Company’s failure to take corrective action based on the Form 483. On this news, Beta Bionics’ stock price fell $0.96, or 6.5%, to close at $13.83 per share on January 30, 2026.
Then, on February 24, 2026, the FDA publicly released its warning letter, revealing the FDA’s concerns with iLet’s underlying issues and stating that any iLet malfunction or hypoglycemia requiring medical intervention must be reported to the FDA. On this news, Beta Bionics’ stock price fell $0.50, or 3.7%, to close at $12.89 per share on February 25, 2026.